Cullinan Therapeutics, Inc.
NDA submitted for zipalertinib; potential $130M in payments.
1 source·02/10, 10:33·sec.gov
Cullinan presents promising Phase 1 study results.
1 source·08/12, 15:36·sec.gov
Cullinan terminates license for cancer therapy CLN-617.
1 source·21/11, 21:32·sec.gov
10-Q form submitted!
1 source·06/11, 12:16·sec.gov
Company reports strong cash reserves and financial stability.
1 source·06/11, 12:06·sec.gov
CLN-049 shows promising results in AML/MDS trial.
1 source·03/11, 14:20·sec.gov
Updated timeline for clinical data announcement.
1 source·04/09, 10:06·sec.gov
10-Q form submitted!
1 source·07/08, 11:42·sec.gov
Two directors resigned; two new directors appointed.
1 source·07/08, 11:11·sec.gov
Annual meeting outcomes and executive decisions reported.
1 source·12/06, 20:26·sec.gov
Cullinan Therapeutics Licenses Rights to Velinotamig, a Clinical-Stage BCMA-Directed Bispecific T Cell Engager, from Genrix Bio for Development in Autoimmune Diseases
·finviz.com·04/06, 20:10
Cullinan Therapeutics to Host Analyst and Investor Event at 2025 ASCO Annual Meeting and Participate in Jefferies 2025 Global Healthcare Conference
·finviz.com·29/05, 11:07
Cullinan Therapeutics, Taiho Pharmaceutical, and Taiho Oncology to Present Positive Results from Pivotal Phase 2b REZILIENT1 Trial of Zipalertinib at ASCO 2025
·finviz.com·22/05, 21:19
Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results
·finviz.com·08/05, 11:25
Cullinan Therapeutics to Initiate Study of CLN-978, a Bispecific CD19 T Cell Engager Administered Subcutaneously, in Patients with Sj gren's Disease in the United States
·globenewswire.com·29/04, 11:07